Melperone

 ( Atypical Antipsychotics ) 

Melperone ( Bunil (Portugal), Buronil (Austria, Belgium, Czech Republic, Denmark, Finland^†, Netherlands^†, Norway^†, Sweden), Eunerpan (Germany)) is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.

---

Marketing and indications It has been tried in treatment-resistant cases of schizophrenia with some (albeit limited) success. It has also been reported effective in the treatment of Levodopa and other forms of psychosis in Parkinson's diseaseBarbato L, Monge A, Stocchi F, Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Funct Neurol. 1996 Aug;11(4):201–7. (although a multicentre, double-blind, placebo-controlled study conducted in 2012 failed to support these findings). It is also known to possess anxiolytic properties. It is marketed in the following countries:

• Austria
• Czech Republic
• Denmark
• Estonia
• Finland
• Germany
• Iceland
• Lithuania
• Latvia
• Portugal
• Sweden

---

Adverse effects Melperone is reported to produce significantly less weight gain than clozapine and approximately as much weight gain as typical antipsychotics. It is also purported to produce around as much prolactin secretion as clozapine (which is virtually nil). It is also purported to produce sedative effects and QT interval prolongation. It is also known to produce less extrapyramidal side effects than the first-generation (typical) antipsychotic, thiothixene. It can also produce (usually relatively mild) dry mouth.

Other common adverse effects include

• Constipation
• Diarrhea
• Nausea
• Vomiting
• Appetite loss
• Hypersalivation (drooling)
• Extrapyramidal side effects (e.g. tremor, dystonia, hypokinesis, akathisia, )
• Insomnia
• Agitation
• Headache
• Dizziness
• Fatigue
• Miosis
• Mydriasis
• Blurred vision
• Elevated liver enzymes (esp. ALT and GGTP)

Rare adverse effects include

• Tardive dyskinesia
• Neuroleptic malignant syndrome
• Blood dyscrasias (pancytopenia, agranulocytosis, leukopenia, thrombocytopenia, etc.)

Unknown frequency adverse effects include

• Seizures (probably rare/uncommon)
• Increased intraocular pressure
• Intrahepatic cholestasis (probably rare)
• Orthostatic hypotension (probably common)
• Arrhythmias
• Rash
• Hyperprolactinemia (which can lead to e.g. galactorrhea, gynecomastia)
• Weight gain
• Increased appetite

---

Interactions Melperone is reported to be a CYP2D6 inhibitor.

---

Pharmacology Melperone binds to the dopamine D₂ receptor, just like all other clinically utilized antipsychotics, but it does so with a very low affinity and hence may be liable to rapidly dissociate from the D₂ receptor hence potentially giving it the profile of an atypical antipsychotic.

2,200
3,400
230
2,100
1,254
578
180
150
>10,000
2,400
>10,000
4,400
>10,000
194
347
555
580

---

Synthesis For the last step of the synthesis the sidechain 4-Chloro-4'-Fluorobutyrophenone 3874-54-2 ( 1) is attached to 4-Methylpiperidine (4-Pipecoline) 626-58-4 ( 2).

---

See also

• Pipamperone

---

External links

• PubChem Substance

Post Comment